[1]韩 鹏,张伯翔,杨艺员,等.非小细胞肺癌组织中NDUFA4L2的表达及其临床意义[J].陕西医学杂志,2025,54(4):435-440,457.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.001]
　HAN Peng,ZHANG Boxiang,YANG Yiyuan,et al.Expression of NDUFA4L2 in non-small cell lung cancer and its potential clinical significance[J].,2025,54(4):435-440,457.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.001]
点击复制

非小细胞肺癌组织中NDUFA4L2的表达及其临床意义
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年4期
页码:
435-440,457
栏目:
基础研究
出版日期:
2025-04-05

文章信息/Info

Title:
Expression of NDUFA4L2 in non-small cell lung cancer and its potential clinical significance
作者:
韩 鹏1; 2; 张伯翔3; 杨艺员1; 李慧婕1; 许 惠1; 梁一倩1
(1.西安交通大学第一附属医院核医学科,陕西 西安710061; 2.西安交通大学第一附属医院耳鼻咽喉头颈外科,陕西 西安710061; 3.西安交通大学第一附属医院胸外科,陕西 西安710061)
Author(s):
HAN Peng1; 2; ZHANG Boxiang3; YANG Yiyuan1; LI Huijie1; XU Hui1; LIANG Yiqian1
(1.Department of Nuclear Medicine,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China; 2.Department of Otolaryngology-Head and Neck Surgery,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China; 3.Department of Thoracic Surgery,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China)
关键词:
非小细胞肺癌;  肺鳞癌;  肺腺癌;  NDUFA4L2;  预后;  免疫组化
Keywords:
Non-small cell lung cancer;  Lung squamous cell carcinoma;  Lung adenocarcinoma;  NDUFA4L2;  Prognosis;  Immunohistochemistry
分类号:
R734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2025.04.001
文献标志码:
A
摘要:
目的:研究非小细胞肺癌(NSCLC)患者肿瘤及正常肺组织中NDUFA4L2的表达差异,探讨其与患者预后及临床病理特征的关联,以期为NSCLC的诊断与治疗提供新的参考方向。方法:应用Oncomine和癌症基因图谱(TCGA)数据库,比较分析NDUFA4L2在NSCLC与正常肺组织中的表达水平; 应用Kaplan-Meier生存曲线分析和Log-rank检验,评估NDUFA4L2表达水平与预后的关系。收集45例NSCLC肿瘤组织标本和癌旁非肿瘤组织,应用RT-PCR及免疫组化方法检测NDUFA4L2的表达情况。结果:通过Oncomine和TCGA数据库分析表明,与正常肺组织比较,肺鳞癌组织NDUFA4L2 mRNA表达量显著增高(P<0.001),而肺腺癌和大细胞肺癌组织中NDUFA4L2 mRNA表达水平与正常肺组织比较无统计学差异(P值分别为0.924和0.165); Kaplan-Meier生存分析指出NDUFA4L2表达水平与肺鳞癌患者总生存期显著相关(P=0.019),且高表达提示预后不良。此外,RT-PCR和免疫组化检测也指出,肺鳞癌组织NDUFA4L2 mRNA和蛋白表达水平较癌旁非肿瘤组织显著增高(P值分别为<0.001和0.008),并且与肺鳞癌的TNM分期呈正相关(P=0.030); 肺腺癌组织NDUFA4L2 mRNA和蛋白表达与癌旁非肿瘤组织比较无统计学差异(P值分别为0.567和0.405)。结论:NDUFA4L2在肺鳞癌组织中呈特异性表达,其高表达水平与患者的不良预后密切相关。
Abstract:
Objective:To investigate NDUFA4L2 expression in tumor and normal lung tissues of non-small cell lung cancer(NSCLC)patients and analyze its correlation with prognosis and clinicopathological features,providing new insights for the diagnosis and treatment of NSCLC.Methods:The Oncomine and The Cancer Genome Atlas(TCGA)databases were used to compare NDUFA4L2 expression levels in NSCLC and normal lung tissues.The correlation between NDUFA4L2 expression and patient prognosis was analyzed by plotting Kaplan-Meier survival curves and performing log-rank tests.Forty-five NSCLC tumor tissue samples and adjacent nontumor tissues were collected,and NDUFA4L2 expression was detected using RT-PCR and immunohistochemistry(IHC)methods.Results:Analysis of the Oncomine and TCGA databases showed significantly higher mRNA levels of NDUFA4L2 in lung squamous cell carcinoma(LUSC)tissues compared to normal lung tissues(P<0.001).However,no significant differences were observed in NDUFA4L2 mRNA expression between normal lung tissues and those with lung adenocarcinoma(LUAD)or large cell lung carcinoma(P=0.924 and P=0.165,respectively).Kaplan-Meier survival analysis indicated that NDUFA4L2 expression levels were significantly associated with overall survival in patients with LUSC(P=0.019),with high expression indicating a poor prognosis.Additionally,RT-PCR and IHC also showed that the expression levels of NDUFA4L2 mRNA and protein were markedly elevated in LUSC tissues compared to adjacent nontumor tissues(P<0.001 and P=0.008,respectively),and positively correlated with the TNM stage of LUSC(P=0.030).There was no significant difference in NDUFA4L2 mRNA and protein expression between LUAD and adjacent nontumor tissues(P=0.567 and P=0.405,respectively).Conclusion:NDUFA4L2 is specifically expressed in LUSC tissues,and its overexpression is associated with poor prognosis in patients with LUSC.

参考文献/References:

[1] KOCARNIK J M,COMPTON K,DEAN F E,et al.Cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted life years for 29 cancer groups from 2010 to 2019:A systematic analysis for the global burden of disease study 2019[J].JAMA Oncol,2022,8(3):420-444.
[2] HAN B,ZHENG R,ZENG H,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
[3] WANG X,ZHANG C,DUAN B J,et al.Forkhead box N1 is possibly a novel biomarker and prognostic indicator for patients with squamous cell lung carcinoma[J].Int J Med Sci,2024,21(15):3058.
[4] 梁乐乐,王鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227-1230.
[5] SANMARCO L M,RONE J M,POLONIO C M,et al.Lactate limits CNS autoimmunity by stabilizing HIF-1α in dendritic cells[J].Nature,2023,620(7975):881-889.
[6] PILTTI J,BYGDELL J,QU C,et al.Effects of long-term low oxygen tension in human chondrosarcoma cells[J].J Cell Biochem,2018,119(2):2320-2332.
[7] PANWOON C,SEUBWAI W,THANEE M,et al.Identification of novel biomarkers to distinguish clear cell and non-clear cell renal cell carcinoma using bioinformatics and machine learning[J].PLoS One,2024,19(6):e0305252.
[8] ZHOU L,MAO L H,LI X,et al.Transcriptional regulation of NDUFA4L2 by NFIB induces sorafenib resistance by decreasing reactive oxygen species in hepatocellular carcinoma[J].Cancer Sci,2023,114(3):793-805.
[9] ALIDOUSTY C,BECKER A,BINOT E,et al.Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung[J].Gene,2024,895:148018.
[10] SHEN Y,CHEN J Q,LI X P.Differences between lung adenocarcinoma and lung squamous cell carcinoma:Driver genes,therapeutic targets,and clinical efficacy[J].Genes Dis,2024:101374.
[11] ZHANG J G,ZHANG J Z,YUAN C.Establishment of the prognostic index of lung squamous cell carcinoma based on immunogenomic landscape analysis[J].Cancer Cell Int,2020,20:330.
[12] YUAN H,LIU J,ZHANG J.The current landscape of immune checkpoint blockade in metastatic lung squamous cell carcinoma[J].Molecules,2021,26(5):1392.
[13] SPICER J D,GARASSINO M C,WAKELEE H,et al.Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer(KEYNOTE-671):A randomised,double-blind,placebo-controlled,phase 3 trial[J].The Lancet,2024,404(10459):1240-1252.
[14] HSU E C,WU K L,TSAI Y M,et al.Real-world treatment pattern and prognostic factors of stage Ⅳ lung squamous cell carcinoma patients[J].The Kaohsiung Journal of Medical Sciences,2022,38(10):1001-1011.
[15] LIN Y,XIE H,ZHAO W,et al.NDUFA4L2 is a novel biomarker for colorectal cancer through bioinformatics analysis[J].Medicine(Baltimore),2023,102(44):e35893.
[16] ZHENG Q,LU C,YU L,et al.Exploring the metastasis-related biomarker and carcinogenic mechanism in liver cancer based on single cell technology[J].Heliyon,2024,10(6):e27473.
[17] ROGERS Z J,COLOMBANI T,KHAN S,et al.Controlling pericellular oxygen tension in cell culture reveals distinct breast cancer responses to low oxygen tensions[J].Adv Sci(Weinh),2024,11(30):e2402557.
[18] NISAR H,SANCHIDRIÁ N G P M,BRAUNY M,et al.Hypoxia changes energy metabolism and growth rate in non-small cell lung cancer cells[J].Cancers(Basel),2023,15(9):2472.
[19] BHANDARI V,HOEY C,LIU L Y,et al.Molecular landmarks of tumor hypoxia across cancer types[J].Nat Genet,2019,51(2):308-318.
[20] QANNITA R A,ALALAMI A I,HARB A A,et al.Targeting hypoxia-inducible Factor-1(HIF-1)in cancer:Emerging therapeutic strategies and pathway regulation[J].Pharmaceuticals,2024,17(2):195.
[21] PANDEY S,SINGH R,HABIB N,et al.Regulation of hypoxia dependent reprogramming of cancer metabolism:Role of HIF-1 and its potential therapeutic implications in leukemia[J].Asian Pac J of Cancer Prev,2024,25(4):1121.
[22] 戚新春,易建华.长链非编码RNA BCYRN1对脑胶质瘤大鼠HIF-1α/VEGF信号通路和血管生成的作用机制[J].陕西医学杂志,2023,52(4):376-379.
[23] 张素冰,高辉,赵滨滨,等.罗哌卡因对骨肉瘤细胞增殖、侵袭及雷帕霉素靶蛋白/缺氧诱导因子1α信号通路的影响[J].陕西医学杂志,2023,52(6):666-670.
[24] LI Y,ZHANG Y,LI X,et al.Status of hypoxia-inducible factor-1α expression in non-small cell lung cancer[J].Pharmazie,2021,76(9):404-411.
[25] LUO Z,TIAN M,YANG G,et al.Hypoxia signaling in human health and diseases:Implications and prospects for therapeutics[J].Signal Transduct Target Ther,2022,7(1):218.
[26] 陈嵘,李淑敏,李旭华,等.软坚散结方调控小鼠HIF-1α糖酵解分子转导抑制肝肿瘤细胞增殖机制研究[J].陕西中医,2023,44(7):839-842.
[27] KUBALA J M,LAURSEN K B,SCHREINER R,et al.NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma[J].Cancer Biol Ther,2023,24(1):2170669.
[28] YE N,WANG Y,JIANG P,et al.Hypoxia-induced the upregulation of NDUFA4L2 promoted colon adenocarcinoma progression through ROS-mediated PI3K/AKT pathway[J].Cytotechnology,2023,75(6):461-472.
[29] XU W N,YANG R Z,ZHENG H L,et al.NDUFA4L2 regulated by HIF-1alpha promotes metastasis and epithelial-mesenchymal transition of osteosarcoma cells through inhibiting ROS production[J].Front Cell Dev Biol,2020,8:515051.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(4):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(4):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(4):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(4):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(4):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(4):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
　LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(4):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]

备注/Memo

备注/Memo:
[基金项目]国家自然科学基金资助青年项目(81902322); 陕西省自然科学基础研究计划(2020JQ-526、2023-JC-YB-791); 西安交通大学第一附属医院基金资助项目(2021ZYTS-02)
更新日期/Last Update: 2025-04-07